EGFR-mutated non-small-cell lung cancer transformation into small-cell lung cancer after tyrosine kinase inhibitors: let us think about liquid biopsy!

被引：0
|
作者：
Pezzuto, F. [1 ]
Fortarezza, F. [1 ]
Lunardi, F. [1 ]
Tauro, V. [1 ]
Frega, S. [1 ]
Pasello, G. [1 ]
Calabrese, F. [1 ]
机构：
[1] Univ Padua, Padua, Italy
来源：
VIRCHOWS ARCHIV | 2021年 / 479卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
OFP-23-003
引用
收藏
页码：S50 / S50
页数：1
相关论文
共 50 条
  • [31] Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
    Occhipinti, Mario
    Brambilla, Marta
    Galli, Giulia
    Manglaviti, Sara
    Giammaruco, Maristella
    Prelaj, Arsela
    Ferrara, Roberto
    De Toma, Alessandro
    Proto, Claudia
    Beninato, Teresa
    Zattarin, Emma
    Lo Russo, Giuseppe
    Gelibter, Alain Jonathan
    Simmaco, Maurizio
    Preissner, Robert
    Garassino, Marina Chiara
    De Braud, Filippo
    Marchetti, Paolo
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (05):
  • [32] Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR plus NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
    Saalfeld, F. C.
    Moeller, J.
    Michels, S.
    Grohe, C.
    Wiesweg, M.
    Schubart, C.
    Alt, J.
    Griesinger, F.
    Kauffmann-Guerrero, D.
    Kulhavy, J.
    Overbeck, T. R.
    Pelusi, N.
    Rohde, G.
    Wesseler, C.
    Vathiotis, I.
    Veluswamy, R.
    Illini, O. M.
    Rothschild, S. I.
    Christopoulos, P.
    Wermke, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [33] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [34] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    Current Treatment Options in Oncology, 2016, 17
  • [35] Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
    Rath, Barbara
    Plangger, Adelina
    Hamilton, Gerhard
    CANCER DRUG RESISTANCE, 2020, 3 (02) : 171 - 178
  • [36] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [37] Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
    Thompson, Jonathan R.
    Menon, Smitha P.
    Dy, Grace K.
    ADMET AND DMPK, 2016, 4 (03): : 186 - 211
  • [38] Pyrimidine derivatives as EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: A comprehensive review
    Kizhakkedath Ratheesh, Anandu
    Pottankottu Jayan, Ajay
    Presanna, Aneesh Thankappan
    Nirmala, Saiprabha Vijayakumar
    CHEMICAL BIOLOGY & DRUG DESIGN, 2022, 100 (04) : 599 - 621
  • [39] Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases
    Flippot, R.
    Auclin, E.
    Biondani, P.
    Le Rhun, E.
    Adam, J.
    Planchard, D.
    Caramella, C.
    Le Pechoux, C.
    Lacroix, L.
    Gazzah, A.
    Mezquita, L.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S467 - S467
  • [40] Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
    Kim, Toe-You
    Han, Soe-Won
    Bang, Yung-Jue
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2007, 7 (06) : 821 - 836
12345